Cargando…
SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase
Sorafenib, a first-line drug for advanced hepatocellular carcinoma (HCC), shows a favorable anti-tumor effect while resistance is a barrier impeding patients from benefiting from it. Thus, more efforts are needed to lift this restriction. Herein, we first find that solute carrier family 27 member 5...
Autores principales: | Xu, Feng-li, Wu, Xiao-hong, Chen, Chang, Wang, Kai, Huang, Lu-yi, Xia, Jie, Liu, Yi, Shan, Xue-feng, Tang, Ni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837139/ https://www.ncbi.nlm.nih.gov/pubmed/36635256 http://dx.doi.org/10.1038/s41419-023-05558-w |
Ejemplares similares
-
ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma
por: Huang, Wenbin, et al.
Publicado: (2021) -
Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de‐palmitoylation
por: Shi, Zhehao, et al.
Publicado: (2023) -
GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis
por: Wang, Qiujie, et al.
Publicado: (2021) -
Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis
por: Li, Yan, et al.
Publicado: (2023) -
SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma
por: Huang, Chao-Yuan, et al.
Publicado: (2022)